-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the advancement of medical reform policies such as consistency evaluation and centralized procurement, the innovation and transformation of the pharmaceutical industry has become a general trend
.
It is worth noting that although the number of domestic biomedical innovation companies is increasing, the research and development of new drugs has always been characterized by high R&D investment, high risk, and long payback period
.
Therefore, in order to solve the dilemma of insufficient innovation, more and more pharmaceutical companies have begun to introduce innovative projects to further enrich their product lines through the "authorized introduction" model
.
On November 4, Shanghai Pharmaceuticals issued an announcement stating that its subsidiary Shanghai Shangyao Xinya Pharmaceutical Co.
, Ltd.
and Phagelux.
Inc.
have signed a "cooperation agreement" with a price not exceeding US$50.
5 million (excluding sales commissions).
Foreign) the transaction amount to obtain the right to develop, produce, register, distribute, sell, market, promote and sublicense the new anti-bacterial infection drug ClyO project in Mainland China, Hong Kong and Macau
.
On October 21, Luoxin Pharmaceutical issued an announcement that the company's subsidiary Shandong Luoxin and Austria Marinomed Biotech AG ("Marinomed") signed a "license agreement", Shandong Luoxin will obtain Budesolv® budesonide solution nasal spray Exclusive development, production and commercialization rights in the Greater China Region (including Mainland China, Hong Kong and Macau Special Administrative Regions, and Taiwan)
.
The industry believes that the cooperation will help to further enrich Luoxin Pharmaceutical's product line and consolidate the company's dominant position in the field of respiratory diseases
.
On October 28, Shanghai Pharmaceuticals also announced that its wholly-owned subsidiary Shanghai Pharmaceutical Xinyi and KoBioLabs.
Inc.
(KoBioLabs) have reached a licensing cooperation to obtain the development of new probiotic drugs KBL697 and KBL693 projects in China (including Hong Kong, Macau and Taiwan) , Production, registration, distribution, sales, marketing, promotion and relicensing rights, including all indications of KBL697 and KBL693 as medicines, as well as the exclusive rights of KBL697 and KBL693 as food, health products, and special medical foods
.
According to the agreement, KoBioLabs can receive US$107 million in related payments
.
From an overall point of view, license in has obviously become one of the rapid development methods for many innovative pharmaceutical companies, which has also made the "authorized introduction" model of innovative medicines continue to gain popularity
.
However, in this context, the industry believes that such pharmaceutical companies will also face many tests, including the ability to judge drugs and BD levels, as well as domestic clinical promotion and sales capabilities
.
It is understood that the current regulators and the market have become quite cautious about the license in model
.
In September of this year, Haihe Pharmaceutical's IPO was officially rejected
.
Within a week, GK Gene's IPO was also rejected
.
Judging from the Shanghai Stock Exchange’s announcement, the reason for the rejection of these two companies is that the regulators have doubts about the "science and innovation content" of the two.
The regulator believes that the issuer has not fully disclosed its independent research and development capabilities and technological advancement
.
In this regard, the industry believes that under the general trend of innovation, pharmaceutical companies still need to have independent research and development capabilities, and cannot rely on the introduction of new drugs to enrich and innovate drug product pipelines
.
In the future, it will be difficult for pharmaceutical companies with a lack of scientific and technological innovation to go public.
Only pharmaceutical companies that focus on innovation and clinical value can gain the recognition of the capital market and have the ability to sustain and develop healthily
.
.
It is worth noting that although the number of domestic biomedical innovation companies is increasing, the research and development of new drugs has always been characterized by high R&D investment, high risk, and long payback period
.
Therefore, in order to solve the dilemma of insufficient innovation, more and more pharmaceutical companies have begun to introduce innovative projects to further enrich their product lines through the "authorized introduction" model
.
On November 4, Shanghai Pharmaceuticals issued an announcement stating that its subsidiary Shanghai Shangyao Xinya Pharmaceutical Co.
, Ltd.
and Phagelux.
Inc.
have signed a "cooperation agreement" with a price not exceeding US$50.
5 million (excluding sales commissions).
Foreign) the transaction amount to obtain the right to develop, produce, register, distribute, sell, market, promote and sublicense the new anti-bacterial infection drug ClyO project in Mainland China, Hong Kong and Macau
.
On October 21, Luoxin Pharmaceutical issued an announcement that the company's subsidiary Shandong Luoxin and Austria Marinomed Biotech AG ("Marinomed") signed a "license agreement", Shandong Luoxin will obtain Budesolv® budesonide solution nasal spray Exclusive development, production and commercialization rights in the Greater China Region (including Mainland China, Hong Kong and Macau Special Administrative Regions, and Taiwan)
.
The industry believes that the cooperation will help to further enrich Luoxin Pharmaceutical's product line and consolidate the company's dominant position in the field of respiratory diseases
.
On October 28, Shanghai Pharmaceuticals also announced that its wholly-owned subsidiary Shanghai Pharmaceutical Xinyi and KoBioLabs.
Inc.
(KoBioLabs) have reached a licensing cooperation to obtain the development of new probiotic drugs KBL697 and KBL693 projects in China (including Hong Kong, Macau and Taiwan) , Production, registration, distribution, sales, marketing, promotion and relicensing rights, including all indications of KBL697 and KBL693 as medicines, as well as the exclusive rights of KBL697 and KBL693 as food, health products, and special medical foods
.
According to the agreement, KoBioLabs can receive US$107 million in related payments
.
From an overall point of view, license in has obviously become one of the rapid development methods for many innovative pharmaceutical companies, which has also made the "authorized introduction" model of innovative medicines continue to gain popularity
.
However, in this context, the industry believes that such pharmaceutical companies will also face many tests, including the ability to judge drugs and BD levels, as well as domestic clinical promotion and sales capabilities
.
It is understood that the current regulators and the market have become quite cautious about the license in model
.
In September of this year, Haihe Pharmaceutical's IPO was officially rejected
.
Within a week, GK Gene's IPO was also rejected
.
Judging from the Shanghai Stock Exchange’s announcement, the reason for the rejection of these two companies is that the regulators have doubts about the "science and innovation content" of the two.
The regulator believes that the issuer has not fully disclosed its independent research and development capabilities and technological advancement
.
In this regard, the industry believes that under the general trend of innovation, pharmaceutical companies still need to have independent research and development capabilities, and cannot rely on the introduction of new drugs to enrich and innovate drug product pipelines
.
In the future, it will be difficult for pharmaceutical companies with a lack of scientific and technological innovation to go public.
Only pharmaceutical companies that focus on innovation and clinical value can gain the recognition of the capital market and have the ability to sustain and develop healthily
.
